MTOR and ovarian carcinoma: Taken together, these data indicate that reduction of BIM protein levels can desensitize ovarian cancer cells to the PI3K/mTOR and BCL-2/BCL-XL drug combination and further highlight the critical role of BIM levels in predicting drug sensitivity.